Tiny tran­scrip­tome biotech se­cures Se­ries A to ramp up au­to­mat­ed R&D ef­forts in race to­ward clin­ic

A Col­orado com­pa­ny is look­ing to re-up its ef­forts to ex­pand and go in­to the clin­ic, and thanks to some fresh cash from an in­vest­ing group, the biotech is head­ed in that di­rec­tion.

Arpeg­gio Bio­sciences an­nounced Wednes­day morn­ing that it suc­cess­ful­ly raised $17 mil­lion in a Se­ries A round, two years af­ter a $3.2 mil­lion seed round and four years af­ter be­ing ini­tial­ly found­ed. CEO and co-founder Joey Azofeifa tells End­points News that the fund­ing will ini­tial­ly go to pipeline de­vel­op­ment and au­tomat­ing its com­pound-screen­ing ef­forts.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER